New study results for prostate cancer drug Xtandi showed that the drug prolonged lives and delayed tumor progression when used before chemotherapy, bringing competition to Johnson & Johnson’s blockbuster drug, Zytiga.
Xtandi, developed by Medivation and Astellas Pharma, was approved in 2012 as a treatment for men with metastatic prostate cancer who had already undergone chemotherapy. The new study showed that the drug is also effective when used before chemotherapy. J&J's Zytiga is also approved for use both before and after chemotherapy.
Read the Ny Times article